What Causes Autoimmune Disease? Genes, Triggers & More

July 25, 2026

Written by: Dr. Akash Chandawarkar, Board Certified Plastic Surgeon, Mirror Plastic Surgery | Last updated: September 9, 2026

Key Takeaways

Autoimmune disease causes involve genetics, environmental triggers, hormones, and somatic mutations that develop during your lifetime.
Recent 2025–2026 research shows no single “autoimmune gene.” Instead, genetic risk clusters within related disease groups, and somatic mutations in immune cells can remove natural immune brakes.
Epstein-Barr virus infection is now considered a near-prerequisite for multiple sclerosis, with a 32-fold increased risk.¹ Smoking, air pollution, and vitamin D deficiency remain key modifiable environmental triggers.
Women account for approximately 80% of autoimmune cases, driven in part by sex-specific genetic switches that heighten inflammatory responses and estrogen-driven B-cell activity.
Understanding these complex causes helps you take proactive steps toward managing your health and long-term autoimmune risk.

Executive Summary: Current Insights Into Autoimmune Disease Causes

Autoimmune diseases arise from a combination of genetic susceptibility, environmental triggers, hormonal factors, and biological changes acquired during life. Approximately 10% of the world’s population is affected by autoimmune diseases, and cases continue to rise worldwide.

Four findings from 2025–2026 research stand out:

A landmark Swedish study of 6.3 million people found no single “autoimmune gene.” Genetic risk clusters within related disease groups, not across all autoimmune conditions.
A Nature study from the Wellcome Sanger Institute identified somatic mutations, or DNA changes acquired during life, in immune cells. These mutations can remove natural immune “brakes” and may drive diseases like Hashimoto’s and Graves’ disease.
A Garvan Institute study identified more than 1,000 genetic switches that behave differently in male and female immune cells, offering a biological explanation for the strong female predominance in conditions such as lupus.
Epstein-Barr virus infection is now considered a near-prerequisite for multiple sclerosis, with a 32-fold increased MS risk documented in a longitudinal study of over 10 million US military personnel.

The Genetic Component: Your Blueprint and Autoimmune Risk

Genetics sets the baseline risk, while environment and lifestyle shape how that risk plays out. A 2026 nationwide Swedish sibling study (Eriksson et al., published in the Journal of Clinical Investigation) analyzed 6,336,615 people and nearly 3.84 million full-sibling pairs. It was the largest study of its kind and found that genetic risk does not stem from a single universal gene. Shared genetic risk instead clusters within related disease groups.

The strongest genetic correlations were between psoriasis and psoriatic arthritis (0.84), autoimmune hepatitis and primary biliary cholangitis (0.68), and lupus and Sjögren’s disease (0.61). By contrast, type 1 diabetes and psoriasis showed a genetic correlation near zero, highlighting how specific these clusters can be.

The study also found that autoimmune disease affected 15.3% of women versus 7.2% of men in the study population. This gap points to additional influences beyond inherited genes alone. A family history raises risk, yet it does not dictate your outcome.

The Somatic Mutation Discovery: A Paradigm Shift

One of the most consequential findings of 2026 came from the Wellcome Sanger Institute. A study published in Nature in April 2026 found that somatic mutations, or DNA changes acquired during life, in immune cells can inactivate immune-checkpoint genes. This change effectively removes the brakes that prevent the immune system from attacking the body’s own tissues.

In patients with Hashimoto’s and Graves’ disease, some B cells carried up to six driver mutations that had accumulated over years before symptoms appeared. Researchers had previously seen this pattern only in cancer, which makes this discovery especially striking.

Professor Chris Goodnow of the Garvan Institute, who was not involved in the study, described the finding as a major leap forward in understanding autoimmune disease pathogenesis. He compared it to fixing the optics on the Hubble Telescope, revealing details that were previously hidden.

For patients, this research shows that autoimmunity can develop from changes that occur during your lifetime as well as from inherited factors. It also supports the development of more precise, targeted treatments that focus on specific immune pathways instead of broad immune suppression.

Environmental Triggers: Everyday Exposures That Shift Risk

Environmental exposures represent the most modifiable dimension of autoimmune disease risk. The following triggers carry the strongest current evidence:

Epstein-Barr Virus (EBV): A landmark longitudinal study of more than 10 million US military personnel found that EBV infection increased MS risk by 32-fold, with no similar risk from other viruses. EBV infects at least 90% of adults worldwide, yet only about 1 in 1,000 infected individuals develops MS, which highlights the role of additional susceptibility factors. In SLE, patients exhibit EBV loads in peripheral blood ranging from approximately 15-fold to 40-fold above controls.
COVID-19: A large binational longitudinal cohort study found that prior COVID-19 infection was associated with a 25–30% increased risk of new-onset autoimmune inflammatory rheumatic diseases within one year.¹ A systematic review found that thyroid peroxidase antibodies doubled after COVID-19 infection (15.7% vs. 7.7% in controls).
Smoking: A 2026 systematic review found smoking and tobacco exposure was the most studied environmental risk factor in autoimmune inflammatory rheumatic diseases, appearing in 215 of 433 included studies (49.7%). It remains the best-established modifiable trigger for seropositive rheumatoid arthritis.
Air Pollution: A 2022 retrospective observational study of more than 81,000 patients found a 7% higher risk of any autoimmune disease for every 10 µg/m³ increase in PM10, with PM2.5 significantly associated with rheumatoid arthritis (aOR 1.559).
Vitamin D Deficiency: Mendelian randomization studies confirm low vitamin D as a causal risk factor for MS, with risk increasing 2-fold for every standard deviation decrease in serum 25-hydroxyvitamin D.

These environmental triggers interact with genetic and hormonal factors, shaping how and when autoimmune diseases emerge.

Hormonal and Sex-Based Factors: Female Predominance Explained

The strong female predominance mentioned earlier reflects deep biological differences in immune regulation. A 2026 study by the Garvan Institute of Medical Research and UNSW Sydney, published in The American Journal of Human Genetics, identified more than 1,000 genetic switches (expression quantitative trait loci) that behave differently in male and female immune cells. The study sequenced more than 1.25 million peripheral blood mononuclear cells from nearly 1,000 healthy people, providing single-cell resolution at an unprecedented scale.

Key findings from the Garvan Institute study include:

Female immune systems are genetically tuned for stronger inflammatory responses, which improves defense against infection but increases autoimmune risk.
Sex-specific genetic switches were mostly located on autosomes, or non-sex chromosomes, which challenges earlier assumptions that sex chromosomes drive most male-female immune differences.
Researchers identified genetic variants that influence the female-biased expression of two genes linked to lupus, a condition that occurs about nine times more often in women than in men.

The estrogen connection adds another layer. Estrogens promote B-cell survival and autoantibody production, while androgens exert immunosuppressive effects. These hormonal shifts help explain why many women notice symptom changes during pregnancy, postpartum, and perimenopause.

Lifestyle and Stress: Everyday Choices That Shape Outcomes

Chronic stress acts as a trigger for autoimmune flares through neuroendocrine pathways. A review published in the International Journal of Molecular Sciences describes how chronic stress leads to impaired HPA axis feedback, glucocorticoid receptor resistance, and cortisol dysregulation. These changes foster a pro-inflammatory state that can trigger or worsen autoimmune diseases such as rheumatoid arthritis, lupus, and multiple sclerosis.

Chronic stress is one of several modifiable factors. The following list summarizes the evidence for each, starting with stress management itself:

Emerging Therapeutic Approaches: From Broad Suppression to Targeted Care

Traditional autoimmune treatments broadly suppress the immune system, which can leave patients vulnerable to infections and other complications. The 2026 somatic mutation research supports a shift toward therapies that target specific immune pathways instead of the entire system. Autoimmune diseases collectively represent the second-largest therapeutic area after oncology, with over 5,500 active drug programs, reflecting this move toward mechanism-based therapies.

Within this landscape, peptide therapy represents a clinically supervised option that aims to modulate immune function and reduce inflammation. Specific peptides focus on defined pathways rather than global suppression:

BPC-157: Targets systemic inflammation and supports muscle, tendon, ligament, and joint repair in preclinical animal studies, although human data remain extremely limited.¹
GHK-CU: Promotes collagen and elastin production while also reducing systemic inflammation.
KPV: Targets inflammation within the gut by inhibiting NF-κB and is transported via PepT1, reducing colitis in animal models. No human clinical trials have yet confirmed a reduction in inflammatory bowel disease risk.

Many peptide therapies, such as insulin and GLP-1s, are FDA-approved and regulated as drugs, while numerous other peptides are not FDA-regulated. The main risk comes from obtaining peptides from unregulated sources without medical supervision. Such sources lack third-party testing for quality, verified dosing, and screening for pre-existing conditions or drug interactions.

Frequently Asked Questions About Autoimmune Causes

Can You Live a Normal Life With an Autoimmune Disease?

A growing number of people live full, active lives with autoimmune conditions. A 2024 study in the Journal of Clinical Investigation estimated that 4.6% of the US population, over 15 million people, has been diagnosed with at least one autoimmune disease, and 34% have more than one. Despite these numbers, most people manage their conditions effectively with a combination of medical treatment, lifestyle changes, and stress management. Early diagnosis and a personalized treatment plan make a major difference in long-term outcomes. Looking ahead, research on somatic mutations and sex-specific genetic pathways supports the development of more targeted therapies and a more hopeful outlook.

What Vitamin Deficiencies Are Linked To Autoimmune Issues?

Vitamin D deficiency has the strongest evidence base among micronutrients. Mendelian randomization studies confirm low vitamin D as a causal risk factor for multiple sclerosis, with risk rising as levels fall, as described earlier. A 2026 review in the International Journal of Molecular Sciences also identified deficiencies in zinc, selenium, and omega-3 fatty acids as impairing regulatory immune circuits and promoting pro-inflammatory cytokine profiles. The VITAL trial found that vitamin D supplementation reduced autoimmune disease incidence by 22%. Clinical researcher Dr. Terry Wahls recommends aiming for the top half of the vitamin D reference range and pairing supplementation with vitamin K to support healthy calcium handling. Comprehensive lab analysis remains the most reliable way to identify and correct your specific deficiency profile.

How Serious Is an Autoimmune Disease?

Severity varies widely by condition and by person. Some autoimmune diseases remain mild and respond well to basic interventions, while others can become life-altering or life-threatening if left untreated. Autoimmune diseases affect approximately 10% of the global population, and the strong female predominance described earlier highlights the scale of impact on women. With early diagnosis and modern treatment approaches, including emerging options like medically supervised peptide therapy, many people achieve remission and maintain excellent quality of life. The 2026 research on somatic mutations offers particular hope by supporting more precise, targeted treatments that may eventually replace broad immune suppression in many cases.

Can Stress Trigger Autoimmune Diseases?

Chronic stress can trigger autoimmune flares and may contribute to disease onset in susceptible individuals. It acts through the hypothalamic-pituitary-adrenal (HPA) axis and related neuroendocrine pathways. A 2026 review in Autoimmunity Reviews describes how chronic stress leads to glucocorticoid resistance and heightened inflammatory signaling. A 2023 systematic review and meta-analysis found a significant association between stressful life events and Graves’ disease onset. Stress-management interventions, including mindfulness-based stress reduction and cognitive-behavioral approaches, have been shown to reduce inflammatory markers and, in some studies, antibody titers. Chronic post-traumatic stress disorder has also been linked to common autoimmune diseases, including Graves’ disease and Hashimoto’s thyroiditis, and childhood psychosocial stressors have been associated with earlier adult-onset rheumatoid arthritis.

What Is the Role of the Gut Microbiome in Autoimmune Disease?

The gut microbiome plays a central role in shaping autoimmune risk. In rheumatoid arthritis, reduced microbial diversity, loss of short-chain fatty acid-producing bacteria, and expansion of specific bacterial taxa are linked to impaired gut barrier integrity, enhanced pro-inflammatory immune responses, and increased autoantibody production. Animal studies show that depleting the microbiota reduces disease severity, while recolonization restores pathogenic responses. In daily life, dietary strategies such as increasing fiber intake, adding fermented foods, and following anti-inflammatory dietary patterns offer accessible ways to influence your immune environment. A personalized plan, guided by lab analysis, helps identify which microbiome-focused interventions are most relevant for you.

Conclusion: Turning Research Into Action for Your Health

Autoimmune disease causes involve genetic susceptibility, environmental triggers, hormonal factors, and lifestyle influences that interact over time. The 2025–2026 research revolution, from somatic mutations to sex-specific genetic switches to the near-causal link between EBV and MS, is reshaping our understanding and expanding future treatment options.

Use these findings to guide practical steps:

Focus on what you can change, including environmental and lifestyle factors that influence your risk and disease trajectory.
Address vitamin D status, manage chronic stress, avoid smoking, maintain a healthy weight, and prioritize an anti-inflammatory dietary pattern.
Partner with a knowledgeable healthcare provider who understands both conventional and emerging approaches, including medically supervised peptide therapy, and who can design a protocol around your specific labs and physiology.

The future of autoimmune care is increasingly personalized, targeted, and grounded in your unique biology.

This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before making any health decisions. Peptide therapies are not FDA-regulated and results may vary.

¹ Results may vary from person to person. Editorial content, before and after images, and patient testimonials do not constitute a guarantee of specific results.

Peptide therapy is intended for wellness and optimization purposes and is not prescribed to diagnose, treat, cure, or prevent disease unless specifically stated. Many peptides are not FDA-approved and may be used off-label. Some have limited long-term safety data, with a potential for unknown risks, complications, or desensitization with prolonged use.